Rein Therapeutics, Inc.
Business
Rein Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for orphan pulmonary and fibrosis indications. The company's lead candidate, LTI-03, is a peptide in Phase 2 development for idiopathic pulmonary fibrosis, with Phase 1b data showing biomarker improvements in epithelial protection and anti-fibrotic activity. LTI-01, a fibrinolytic for loculated pleural effusion, completed Phase 2a trials but development is paused; preclinical programs in cystic fibrosis and systemic fibrosis are also suspended pending additional financing. The company relies on third-party contract manufacturers and has no in-house production or sales capabilities.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and development | 11 | 14 | 4 | 18 | 17 | |
| General and administrative | 11 | 14 | 11 | 10 | 10 | |
| Impairment loss on intangible assets | 29 | 37 | 0 | — | — | |
| Total operating expenses | 51 | 65 | 16 | 28 | 27 | |
| Loss from operations | −51 | −65 | −16 | −28 | −27 | |
| Other income, net | 48,000 | 685,000 | 544,000 | 318,000 | 441,000 | |
| Income tax benefit | 712,000 | 2 | 0 | — | — | |
| Net loss | −50 | −63 | −16 | −27 | −26 | |
| Net loss per share - basic | −1.96 | −3.51 | −3.42 | −6.02 | −5.89 | |
| Net loss per share - diluted | −1.96 | −3.51 | −3.42 | −6.02 | −5.89 | |
| Weighted average common shares outstanding - basic | 25 | 18 | 5 | 5 | 4 | |
| Weighted average common shares outstanding - diluted | 25 | 18 | 5 | 5 | 4 | |
| Unrealized (loss) gain on investments, net of tax of $0 | −15,000 | 45,000 | 48,000 | −35,000 | −11,000 | |
| Foreign currency translation adjustments | −29,000 | 0 | — | — | — | |
| Total other comprehensive (loss) gain | −44,000 | 45,000 | −15,000 | −35,000 | −11,000 | |
| Total comprehensive loss | −50 | −63 | −16 | −27 | −26 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 13 | 17 | 5 | 4 | |
| Prepaid expenses and other current assets | 1 | 792,000 | 882,000 | 606,000 | 2 | |
| Total current assets | 4 | 14 | 18 | 22 | 48 | |
| Property and equipment, net | 0 | 1,000 | 19,000 | 70,000 | 128,000 | |
| Goodwill | 6 | 6 | 6 | — | — | |
| Intangible assets | 14 | 42 | 79 | — | — | |
| Other non-current assets | 2,000 | 2,000 | 2 | 24,000 | 24,000 | |
| Total assets | 24 | 62 | 106 | 22 | 48 | |
| Accounts payable | 4 | 911,000 | 1 | 2 | 1 | |
| Accrued expenses and other current liabilities | 2 | 5 | 3 | 2 | 3 | |
| Total current liabilities | 6 | 6 | 4 | 3 | 5 | |
| Deferred tax liability | 1 | 2 | 3 | — | — | |
| Other long-term liability | 0 | 277,000 | — | — | — | |
| Total liabilities | 7 | 8 | 8 | 3 | 5 | |
| Commitments and contingencies (Note 12) | — | — | — | — | — | |
| Convertible preferred stock, $0.001 par value, 5,000,000 shares authorized at December 31, 2025 and at December 31, 2024; 24,610 shares issued and 12,232 shares outstanding at December 31, 2025 and at December 31, 2024 | 45 | 45 | 91 | — | — | |
| Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2025 and at December 31, 2024; 27,550,222 shares and 21,666,012 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 113,000 | 108,000 | 91,000 | 91,000 | 91,000 | |
| Additional paid-in capital | 373 | 361 | 295 | 291 | 289 | |
| Accumulated other comprehensive loss | −62,000 | −18,000 | −63,000 | −48,000 | −13,000 | |
| Accumulated deficit | −401 | −351 | −289 | −273 | −245 | |
| Total liabilities, convertible preferred stock and stockholders' equity | 24 | 62 | 106 | 22 | 48 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −50 | −63 | −16 | −27 | −26 | |
| Commitment fee related to Pre-Paid Advance agreement | 300,000 | 0 | — | — | — | |
| Original issue discount related to Pre-Paid Advance agreement | 150,000 | 0 | — | — | — | |
| Depreciation and amortization expense | 1,000 | 63,000 | 119,000 | 169,000 | 121,000 | |
| Stock-based compensation expense | 2 | 1 | 1 | 2 | 2 | |
| Prepaid expenses and other current assets | −319,000 | 134,000 | 51,000 | 2 | −291,000 | |
| Other assets | 0 | 2 | −3,000 | — | −24,000 | |
| Accounts payable | 3 | −279,000 | −5 | 510,000 | −386,000 | |
| Operating lease liabilities | 0 | −48,000 | −65,000 | −129,000 | −66,000 | |
| Accrued expenses and other current liabilities | −3 | 2 | −382,000 | −2 | 1 | |
| Other long-term liabilities | −277,000 | 277,000 | 0 | — | — | |
| Deferred tax liabilities | −712,000 | −2 | 0 | — | — | |
| Net cash used in operating activities | −19 | −22 | −20 | −25 | −24 | |
| Proceeds from issuance of common stock, net of offering costs | 2 | 11 | 0 | — | — | |
| Proceeds from Pre-Paid Advances, net of discounts | 3 | 0 | — | — | — | |
| Proceeds from issuance of common stock in connection with stock option exercises | 4,000 | 143,000 | 0 | — | 74,000 | |
| Proceeds from issuance of common stock in connection with Warrant Exercises, net of costs | 2 | 0 | — | — | — | |
| Proceeds from issuance of warrants, net of offering costs | 481,000 | 7 | 0 | — | — | |
| Proceeds from Warrant Exchanges, net of offering costs | 3 | 0 | — | — | — | |
| Proceeds from warrant exercises with common stock subscribed | 22,000 | 0 | — | — | — | |
| Net cash provided by financing activities | 10 | 18 | 16 | — | 56 | |
| Effect of exchange rate changes on cash and cash equivalents | −44,000 | 0 | −63,000 | — | — | |
| Net decrease in cash and cash equivalents | −10 | −4 | 12 | 2 | −4 | |
| Unrealized (loss) gain on short-term investments | −15,000 | 37,000 | 48,000 | — | — | |
| Foreign currency translation adjustments | −29,000 | 0 | — | — | — | |
| Issuance of common stock for Pre-Paid Advances and interest accrual | 3 | 0 | — | — | — | |
| Conversion of Series X non-voting convertible preferred stock into common stock shares | 0 | 46 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Rein Therapeutics, Inc.'s CIK number?
Rein Therapeutics, Inc.'s SEC CIK number is 0001420565 (1420565). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Rein Therapeutics, Inc.'s SEC filings?
All of Rein Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Rein Therapeutics, Inc. last report earnings?
Rein Therapeutics, Inc. (RNTX) most recently filed an earnings 8-K with the SEC on May 15, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-25-120824). This is Rein Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Rein Therapeutics, Inc.'s most recent earnings 8-K?
Rein Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 15, 2025 under accession 0001193125-25-120824. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Rein Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →